natgillin/translations-raw huggingface dataset:
The platform according to any one of claims 1 to 14, wherein said three or more chromogenic substances includes the group of 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside, 6-chloro-3-indolyl-beta-D-galactopyranoside, 5-Bromo-4-chloro-3-indolyl-beta-D-glucopyranoside and 5-Bromo-4-chloro-3-indolyl-beta-D-glucuronide. 
Platforma prema bilo kojem od zahtjeva 1 do 14, gdje tri ili više kromogenih tvari obuhvaćaju grupu 5-Brom-4- klor-3-indolil-beta-D-galaktopiranozid, 6-klor-3-indolil-beta-D-galaktopiranozid, 5-Brom-4-klor-3-indolil-beta-D- glukopiranozid i 5-Brom-4-klor-3-indolil-beta-D-glukuronid.
Method according to claim 1, further comprising the phase of detecting the current in at least a conductor connected to the load (16) and disconnecting the same load (16) whenever said current is greater than a pre-established threshold. 
Postupak u skladu s bilo kojim od dosad navedenih zahtjeva, naznačen time da se može detektirati struja barem u vodiču koji je spojen na trošilo (16), i da se isto trošilo (16) odspaja kad god je takva struja veća od prethodno ustanovljenog praga.
The composition of any one of claims 7 to 20, wherein the enteric coating comprises film-forming substances, preferably cellulose acetate phthalate, polyvinyl- acetate phthalate, hydroxypropyl-methyl cellulose phthalate, hydroxypropyl-methyl cellulose acetate succinate, ethylacrylate methacrylic acid copolymer, methylmethacrylate methacrylic acid copolymer, shellac, preferably copolymers of methacrylic acid and methacrylic acid esters such as anionic polymer of methacrylic acid and methacrylates with -COOH groups. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da enterička obloga obuhvaća tvari za formiranje filma, poželjno su to celulozni acetat-ftalat, polivinil-acetat-ftalat, hidroksipropilmetil-celuloza-ftalat, hidroksipropilmetil-celuloza-acetat-sukcinat, kopolimer etilakrilat-metakrilne kiseline, kopolimer metilmetakrilat-metakrilne kiseline, šelak, poželjno kopolimeri metakrilne kiseline i esteri metakrilne kiseline kao što su anionski polimer metakrilne kiseline i metakrilati s -COOH-skupinama.
Use according to any one of claims 1 to 5, or a combination for use according to any one of claims 6 to 10, wherein the hematologic cancer is selected from chronic lymphocytic leukemia, acute lymphoblastic leukemia and non-Hodgkin's lymphoma. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 5, ili kombinacija namijenjena upotrebi u skladu s bilo kojim od patentnih zahtjeva 6 do 10, naznačene time što se hematološki rak bira između kronične limfocitne leukemije, akutne limfoblastične leukemije i nehodgkinovskog limfoma.
After diafiltration to remove SDS and form microaggregates, an IL-2 solution may be subjected to one or more of the following steps: dilution to give a desired final dose; sterilisation, typically by sterile filtration e.g. 
Nakon diafiltracije, da bi odstranio SDS i oblikovali mikroagregati, otopina IL-2 se može podvrgnuti jednom ili više od sljedećih stupnjeva: razrjeđenju, da se dade željena konačna doza; sterilizaciji, tipično sterilnom filtracijom na pr.
A method for the preparation of a pharmaceutical composition containing venlafaxine or a pharmaceutically acceptable salt thereof comprising the steps of 
Postupak dobivanja farmaceutskog pripravka koji sadrži venlafaksin ili njegovu farmaceutski prihvatljivu sol, koji se sastoji od slijedećih koraka:
Pharmaceutical composition according to Claim 8, characterized in that the said pharmaceutically acceptable salt is an addition salt with physiologically acceptable organic or mineral acids or bases. 
Farmaceutski sastav prema zahtjevu 8, naznačen time, da je navedena farmaceutski prihvatljiva sol takva, da je to adicijska sol s fiziološki prikladnim organskim ili mineralnim kiselinama ili lužinama.
The sealing material is geometrically arranged in order to be exposed to the fluid pressure in the capsule enclosure space. 
Materijal za brtvljenje je geometrijski smješten tako da se izlaže fluidu pod tlakom u prostoru koji obuhvaća čahuru.
wherein m is 1, 2, or 3, RF is H or C1-3alkyl, and RE is H, C1-3alkyl, or SO2CH3, and wherein each of the foregoing pyridyl, pyrrolidinyl, piperidinyl, and piperazinyl groups is optionally substituted at one or more carbon atoms with 1, 2, or 3 independent occurrences of R11, and at one or more substitutable nitrogen atoms with R12; 
NH RE LonH gdje je m jednak 1, 2 ili 3, R* jeHili C,3alkil, i R? je H, Crsalkil ili SOL2CH., i pri čemu je svaka od prethodno navedenih piridil, pirolidinil, piperidinil i piperazinil grupa izborno supstituirana na jednom ili više atoma ugljika sa 10
The extended release dosage form of claim 29, wherein the dosage form comprises 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 24 mg, 32 mg, 48 mg or 64 mg of hydromorphone hydrochloride. 
Postupak prema zahtjevu 45, naznačen time da oblik davanja sadrži 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 24 mg, 32 mg, 48 mg ili 64 mg hidromorfon hidroklorida.
A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadrži spoj prema zahtjevu 1 i farmaceutski prihvatljiv nosač.
A kit of parts according to claim 17, wherein said disposable or reusable devices are enemas or paediatric enemas of Fleet type. 
Komplet dijelova za uporabu u skladu s patentnim zahtjevom 17, naznačen time, da su rečene naprave za jednokratnu ili višekratnu uporabu klistiri ili dječji (eng.
The pharmaceutical composition for use according to claim 1, wherein the composition provides steady state plasma levels of 3 a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 5 ng/mL to 500 ng/mL for a duration of from 12 h to 24 h following administration. 
Farmaceutski sastav za upotrebu prema patentnom zahtjevu 1, naznačen time da daje stacionarno stanje razina u plazmi 3 a-hidroksi-3B-metoksimetil-21-(1’-imidazolil)-5a-pregnan-20-ona u rasponu od 5 ng/ml do 500 ng/ml u trajanju od 12 sati do 24 sata nakon davanja.
Repair process 12 may further modify 126 the portable executable file residing in memory (e.g., in RAM) during execution, in which the portable executable file residing in memory during execution is based upon the portable executable file (e.g., based upon PE binary image 20). 
Produkt računalnog programa prema zahtjevu 5, naznačeno time da popravak (106) nevažećeg polja uključuje dinamički popravak (122) nevažećeg polja koji uključuje: izvršenje (124) prijenosne izvršne datoteke; i modificiranje (126) datoteke pohranjene u memoriju tokom izvršenja prijenosne izvršne datoteke, naznačeno time da je datoteka pohranjena u memoriji utemeljena na prijenosnoj izvršnoj datoteci.
coupling a thiol compound of formula 2 with a Montelukast intermediate of formula 3 in the presence of a base in a medium comprising an ionic compound selected from the group consisting of 1-ethyl-3-methylimidazolium bromide, and N-butyl-N-methylpyrrolidium hexafluorophosphate to give the Montelukast acid of formula 1; and 
SH CO2R: s Montelukastovim međuproduktom formule 3 u prisutnosti baze, u mediju koji sadrži tekući ionski spoj, kojeg se bira iz skupine koju čine spojevi formula 4a do 4e: gdje
A developer supply container according to Claim 3, wherein with increase of a volume of the chamber, the pressure in the developer accommodating portion becomes lower than the ambient pressure to substantially clog said discharge opening with the developer. 
Spremnik za dostavu razvijača u skladu s patentnim zahtjevom 2, naznačen time što s povećanjem volumena komore navedenog dijela za crpljenje (2) unutarnji tlak u dijelu za držanje razvijača (1b) postaje niži od tlaka okoliša.
Embodiment No. 5 In a further embodiment of the present invention the process described in embodiments no. 2 to 4 further incorporate an anti oxidants selected from a group comprising Butylated Hydroxy Anisole, Butylated Hydroxy Toluene and the like from about 0.001% (w/w) to 5% (w/w), preferably 0.1% (w/w), more preferably 0.01% (w/w). 
Postupak za proizvodnju kreme s fusidinskom kiselinom prema bilo kojem od patentnih zahtjeva 2, 4, 5, 1 6, naznačen time, da se nadalje antioksidans dodaje u stupnju h patentnog zahtjeva 2 do 5, kod čega se navedeni antioksidans odabire iz skupine koja sadrži butilirani hidroksianisol, butilirani hidroksitoluen i slične, od oko 0,001% (tež.) do 5% (tež.), prvenstveno 0,1% (tež.), pogodnije 0,01% (tež.).
temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C; 
(i) temeprature su dane u Celsius-evim stupnjevima (*C), radnje su provedene pri sobnoj ili temperaturi okoline, dakle pri temperaturi u rasponu od 18-25 "C;
is hydrogen or C1-C4 alkyl; the radical represents an optionally substituted azetidine, pyrrolidine, piperidine, morpholine, oxazepane or 1,2,3,4-tetrahydroisoquinoline ring, wherein each of R6 is independently selected from the group consisting of hydrogen, halogen, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 spirocycloalkyl difluoromethyl, trifluoromethyl, C1-C4 alkyloxy, aryl, heteroaryl, C1-C4 aryloxy or C1-C4 arylalkoxy wherein the aryl group or heteroaryl group is optionally substituted with halogen C1-C4 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl or C1-C4 alkyloxy. 
R> je odabran od vodika, halogena, ili je heterociklički prsten odabran od pirimidin-2-il, piridin-2-il ili pirazin-2-il, koji može biti supstituiran halogenom, Ci-C4 alkilom, fluormetilom, difluormetilom, trifluormetilom ili Cy-Cu alkiloksi; R'je vodik ili C,-Ca alkil; radikal predstavlja azetidin, pirolidin, piperidin, morfolin, oksazepan ili 1,2,3,4-tetrahidroizokinolin prsten koji može biti supstituiran, gdje je svaki od R* neovisno odabran iz skupine koju čine vodik, halogen, C;-C4 alkil, Cs-Cg cikloalkil, C3-Cg spirocikloalkil, difluormetil, trifluormetil, C;-Ca alkiloksi, aril, heteroaril, C;-C4 ariloksi ili Ci-Ca arilalkoksi gdje arilna skupina ili heteroarilna skupina može biti supstituirana halogenom, C;-Cu alkilom, fluormetilom, difluormetilom, trifluormetilom ili C,-C, alkiloksi.
A use according to embodiment 16, wherein the δ-amino-Y-hydroxy-w-aryl alkanoic acid amide derivative is a compound of Formula (I) wherein R1 is 3-methoxypropoxy; R2 is methoxy; and R3 and R4 are isopropyl; or a pharmaceutically acceptable salt thereof. 
Farmaceutski pripravak u skladu sa zahtjevom 18, naznačen time, da derivat amida 5-amino-y-hidroksi-o-aril- alkanoične kiseline je spoj formule (I) gdje Ri je 3-metoksipropoksi; R» je metoksi; te Ra i Ra su izopropil; ili je njegova farmaceutski prihvatljiva sol.
The process according to claim 1, wherein the cation of the at least one water-soluble salt is sodium. The process according to claim 1, wherein the anion of the at least one water-soluble salt is selected from the group consisting of phosphate, dihydrogen phosphate, monohydrogen phosphate, oxalate, silicate, hydrates thereof, and any mixture thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time da je anion navedene kiseline topive u vodi odabran iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, oksalat, silikat, njihove mješavine i njihove hidrate, poželjnije iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, njihove mješavine i njihove hidrate, te najpoželjnije iz skupine koja sadrži dihidrogen fosfat, monohidrogen fosfat, njihove mješavine 1 njihove hidrate.
The composition of claim 11 wherein the composition has a pH range from 6.0 to 9.0, preferably from 7.0 to 8.0. 
Sastav prema zahtjevu 11, naznačeno time da sastav ima raspon pH vrijednosti od 6,0 do 9,0, poželjno od 7,0 do
ANTIBODY SEQUENCES Heavy Chain Variable Region Amino Acid Sequence (SEQ ID NO:1) 
2. - Protutijelo prema zahtjevu 1, naznačeno time da sadrži teški lanac koji sadrži sekvencu aminokiselina SEQ ID NO:
Used without further purification. 
Koristi se dalje bez dodatnog pročišćavanja.
The use of claim 7, wherein said ADlF is selected from sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer. 
Uporaba prema zahtjevu 7, naznačena time da je navedeno stanje ADIF odabrano od seksualne disfunkcije, smanjenog seksualnog libida, hipogonadizma, sarkopenije, osteopenije, osteoporoze, promjena u spoznaji i raspoloženju, depresije, anemije, gubitka kose, pretilosti, endometrioze, raka dojke, raka maternice i karcinoma jajnika.
The patient medical record may be maintained by, for example, a laboratory, physician's office, a hospital, a health maintenance organization, an insurance company, or a personal medical record website. 
Postupak prema patentnom zahtjevu 13, naznačen time što medicinsku dokumentaciju pacijenta vodi laboratorij, ured zaduženog liječnika, bolnica, zdravstvena organizacija, osiguravajuće društvo ili služba internet stranice za osobne zdravstvene kartone.
The incineration grate according to claim 1, wherein spacers are arranged on adjacent contact surfaces between the first and second grate bars. The incineration grate according to claim 1, wherein 
Rešetka za spaljivanje prema jednom ili više prethodnih patentnih zahtjeva, naznačena time da su odstojnici (19) raspoređeni u blizini kontaktnih površina između šipki (A,B) rešetke.
The composite structure according to any preceding claim wherein the mineral containing layer comprises sustainable polymer content of bio-polymers. The composite structure according to any preceding claim wherein the mineral containing layer comprises at least one of the group consisting of starch, wheat and corn. 
Kompozitna struktura sukladno bilo kojem od prethodnih zahtjeva, naznačen time, što sloj mineralnog sastava sadrži barem jednu od skupina koja se sastoji ima sloj koji sadrži mineral koji se dalje mora sastojati od barem jedne grupe sastavljene od škroba, pšenice i kukuruza.
Procedure according to any one of the above claims, in which the separation of carbonates and/or bicarbonates of the liquid fraction resulting from at least partial removal of the culture from the reactor is carried out by precipitation of the corresponding carbonated salts caused by the addition of at least one alkali. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se, nakon koraka u najmanju ruku djelomičnog uklanjanje kulture iz reaktora, razdvajanje čvrste frakcije koja sadrži biomasu i tekuće frakcije koja sadrži karbonate i/ili bikarbonate provede najmanje jednim postupkom, koji se bira iz skupine koju čine
The compound for use according to claim 12, wherein the RNA viral polymerase is a polymerase selected from the group consisting of Dengue fever, influenza A, influenza B, Junin, measles, parainfluenza, Pichinde, Punta Toro, respiratory syncytial, rhinovirus, Rift Valley Fever, SARS, Tacaribe, Venezuelan equine encephalitis, West Nile, and yellow fever viral polymerases. 
Spoj za primjenu prema zahtjevu 5 ili 6, naznačen time da je druga virusna RNK polimeraza izabrana iz grupe koja se sastoji od virusnih polimeraza adenovirusa, influenca A virusa, influenca B virusa, parainfluenca virusa, respiratornog sincicijalnog virusa, rinovirusa, Junin virusa, Pichinde virusa, virusa groznice doline Rift, virusa denga groznice, virusa morbila, virusa žute groznice, Takaribe virusa, virusa venecuelanskog konjskog encefalitisa, virusa Zapadnog Nila, i SARS-CoV virusa.
56, 57 and 58; and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising respectively the amino acid sequences SEQ ID Nos. 
1, 2 i 3, laki lanac koji sadrži CDR-L1, CDR-L2 i CDR-L3 te sadrži aminokiselinsku sekvenciju SEQ ID No.
wherein T and R5 are as defined for formula (I), the compound so obtained optionally being subjected to the action of a pyrophosphate or phosphate compound under basic conditions to yield the compound of formula (I), which compound of formula (I) may be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique, it being understood that, at any time considered appropriate in the course of the above-described process, certain groups (hydroxy, amino . . .) of the reagents or intermediates of synthesis may be protected and then deprotected according to the requirements of synthesis. 
N di pri čemu su T i Rs definirani kao za formulu (I), tako dobiveni spoj se po izboru podvrgava djelovanju spoja pirofosfata ili fosfonata u bazičnim uvjetima, kako bi se dobio spoj formule (I), a spoj formule (I) može biti pročišćen u skladu s uobičajenom tehnikom razdvajanja, i prevodi se, ako je poželjno, u njegove adicijske soli s farmaceutski prihvatljivom kiselinom ili bazom 1 koji se prema potrebi odvajaju u njegove izomere prema uobičajenoj tehnici razdvajanja, podrazumijeva se da se u bilo kojem prikladnom trenutku tijekom gore opisanog postupka, određene skupine (hidroksi, amino...) reagensa ili intermedijera sinteze mogu se zaštititi, a zatim se deprotektirati prema zahtjevima sinteze.
According to a twelfth aspect, the method of the eighth aspect further comprises, for each nozzle group, communicating address data to that nozzle group, the address data identifying one of a plurality of nozzle circuits within the nozzle group to which a conditionally modified firing signal is to be forwarded. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što se dodatno sastoji u, za svaku skupinu mlaznica, slanju adresnih podataka u tu skupinu mlaznica, gdje adresni podaci određuju jedan od više mlazničnih krugova unutar skupine mlaznica u koji treba poslati uvjetno modificirani okidni signal.
The method of claim 2, wherein said brain cancer is a brain metastasis, a glioblastoma, or a glioma. 
Konjugat ili pripravak za uporabu kako je opisano u zahtjevu 15 ili 16, naznačen time da navedeni karcinom je karcinom mozga, poželjno glioblastom ili gliom.
The method of claim 1, wherein the protein binding assay is one of ELISA (enzyme-linked immunosorbent assay), RIA (radioimmunoassay), FIA (fluorescence immunoassay), LIA (luminescence immunoassay), or ILMA immunoluminometric assay. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što ispitivanje vezanjem proteina je jedno od ELISA (enzimski vezanog imunosorbentnog ispitivanja), RIA (radioimunoispitivanja), FIA (fluorescentnog imunoispitivanja), LIA (luminescentnog imunoispitivanja) ili ILMA.
the compound of formula (II): is condensed with 4-nitrobenzoic acid chloride and the compound of formula (XXVIII) is obtained: 
spoj s formulom (II): [image] kondenzira s kloridom 4-nitrobenzojeve kiseline i dobiven je spoj s formulom (XXVIII): [image]
The pharmaceutical composition according to claim 1, wherein the first species of active agent particles is suspended in the suspension medium at a concentration sufficient to provide a delivered dose of glycopyrrolate of up to 10 µg per actuation of the metered dose inhaler. 
prva vrsta čestica aktivnog sredstva sadrži glikopirolat, uključujući bilo koje farmaceutski prihvatljive soli, estere, enantiomere, te smjese njihovih enantiomera ili solvata, gdje najmanje 90% prve vrste čestica aktivnog sredstva po volumenu pokazuje optički promjer od 7 µm ili manji, suspendirane u suspenzijskom mediju u koncentraciji dovoljnoj da osigura unesenu dozu glikopirolata od do 80 µg po aktuaciji inhalatora za odmjerene doze;
In a preferred embodiment, the at least one mismatch or spacer, preferably all mismatches and spacers, is/are within the ten nucleotides of the 3′ end and/or not within the five nucleotides of the 5′ end of the primer oligonucleotide. 
Metoda sukladno bilo kojem patentnom zahtjevu 1-4 ili pribor sukladno patentnom zahtjevu 5 ili 6, pri čemu je najmanje jedno pogrešno sparivanje ili razmaknica unutar 3* kraja sintetiziranog oligonukleotida i/ili nije unutar pet nukleotida 5 kraja sintetiziranog oligonukleotida.
wherein X is Cl or Br, and (0-2) substituting X with PLG by reaction of a reagent PLG-H in the presence of a base, to obtain a compound of formula VI″ 
o gdje X je Clili Br, (0-2) supstitucija X s PLG pomoću reakcije reagensa PLG-H u prisutnosti baze, kako bi se dobio spoj formule II'
wherein each of the above-mentioned substituents on Ring A and Ring B may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an alkanoyl group, a mono- or di-alkylamino group, a carboxyl group, a hydroxy group, a phenyl group, an alkylenedioxy group, an alkyleneoxy group, and an alkoxycarbonyl group; 
S. _R rI Sa R gdje R* je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, alkilnom skupinom, halogenalkilnom skupinom, alkoksi skupinom, halogenalkoksi skupinom, alkilendioksi skupinom, alkilenoksi skupinom ili mono- ili di-alkilamino skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, alkilnom skupinom, halogenalkilnom skupinom, alkoksi skupinom ili halogenalkoksi skupinom; a R* je atom vodika;
The process according to claim 1, wherein in step d) the addition of the at least one water-soluble salt takes place in an aqueous environment having a temperature of above 50° C. 
Postupak prema bilo kojem od zahtjeva 1 do 18, naznačen time da se korak d) i dodavanje navedene kiseline topive u vodi poželjno odvija u vodenoj okolini koja ima temperaturu od iznad 50*C, te poželjno od iznad 60*C.
The Bio Burden was tested by membrane filtration (see the European Pharmacopea, 4th Edition, 2002 Chapter 2.6.12). 
Biološko opterećenje je bilo određeno membranskom filtracijom (vidi European Pharmacopeia, 4. Izdanje, 2002, Poglavlje 2.6.12).
The dried powder was subsequently calcined at 600° C. for 2 hours. The calcined powder was then suspended in pure water, and the beaker containing the suspension was ultrasonicated for 12 hours to break the agglomerates in the powder. 
Suhi prašak je zatim žaren 2 sata pri 600 "C. Žareni prašak je zatim suspendiran u čistoj vodi, a čaša koja sadrži suspenziju je ultrasonificirana kroz 12 sati da se razbiju aglomerati praška.
The system according to any of claims 16 to 23, wherein the two enclosing members are designed to selectively cooperate with the sealing member of the capsule by engaging it with a pinching movement which follows an essentially translational trajectory in its final approach phase. 
Sustav u skladu s bilo kojim od patentnih zahtjeva 15 do 20, u kojemu su dva elementa (9, 13) koji obuhvaćaju čahuru izvedena tako da selektivno zahvaćaju element za brtvljenje (8) čahure (1), zahvaćajući ga s pokretom stezanja, iza čega slijedi uglavnom pravocrtna putanja u njegovoj krajnjoj fazi približavanja.
a fluid outlet in fluid communication with a plumbing fixture; 
izlaz fluida (14) u fluidnoj komunikaciji s vodovodnom instalacijom;
• compressing the dry blend into a solid dosage unit. 
* - komprimiranja suhe mješavine u čvrstu doznu jedinicu.
A transdermal delivery device comprising: a drug containing layer comprising an effective amount of an opioid agonist and a plurality of microspheres dispersed in the drug containing layer, the microspheres comprising an opioid antagonist and wherein the microspheres are in a mean size of from 1 to 300 µm in diameter. 
Uređaj za transdermalno davanje koji sadrži: sloj polimerne matrice koji sadrži opioidni agonist s međusobno izmiješanim mikrosferama koje sadrže opioidni antagonist, te naznačen time da su mikrosfere u promjeru srednje veličine 1 do 500 µm.
In a fourth dog a dose of 1 mg/kg 42-O-(D-fructosylcarbonyl)rapamycin resulted in slight lethargy but the dog quickly recovered. 
U četvrtog psa, doza od 1 mg/kg 42-0-(D-fruktozilkarbonil)rapamicina dovela je do blage letargije, ali pas se brzo oporavio.